SLS
Sellas Life Sciences (NASDAQ: SLS) CEO Angelos Stergiou said AI is transforming drug development by...
Article Summary
HOLD- Sellas Life Sciences (NASDAQ: SLS) CEO Angelos Stergiou said AI is transforming drug development by analyzing genetic and molecular makeup of tumors, allowing researchers to identify which patients are most likely to respond to specific therapies.
- The precision medicine approach can shorten the traditional 10- to 15-year drug development process, with AI-driven biomarker analysis allowing Sellas to identify patients unlikely to response to standard treatments and match them with therapies better suited to their genetic profile.
- Sellas has entered a quiet period ahead of its Phase 3 Regal trial for acute myeloid leukemia treatment, which has recorded 78 of the 80 events needed for final overall survival analysis.
- SELLAS Life Sciences Group is focused on database lock, potential BLA preparations, and advancing its SLS009 program, with retail sentiment remaining in the 'bearish' zone over the past 24 hours.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 0.0% | 25% | 10.0 ptsVery Weak (0.0%) - Minimal expectations |
| Target Price Upside ? | 140.8% | 20% | 100.0 ptsMassive Upside (140.8%) - Target: $27.50 vs Current: $11.42 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -28.1% | 15% | 80.0 ptsSolid Dip (-28.1%) - Good entry zone |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About SLS
- SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
- The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
- It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology.
- SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.